

# MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

<b>CLINICAL BENEFIT</b>	<input type="checkbox"/> MINIMIZE SAFETY RISK OR CONCERN. <input type="checkbox"/> MINIMIZE HARMFUL OR INEFFECTIVE INTERVENTIONS. <input type="checkbox"/> ASSURE APPROPRIATE LEVEL OF CARE. <input type="checkbox"/> ASSURE APPROPRIATE DURATION OF SERVICE FOR INTERVENTIONS. <input checked="" type="checkbox"/> ASSURE THAT RECOMMENDED MEDICAL PREREQUISITES HAVE BEEN MET. <input type="checkbox"/> ASSURE APPROPRIATE SITE OF TREATMENT OR SERVICE.
<b>Effective Date:</b>	<b>RETIRED 7/1/2026</b>

[POLICY RATIONALE](#)  
[CODING INFORMATION](#)

[PRODUCT VARIATIONS](#)  
[DEFINITIONS](#)  
[REFERENCES](#)

[DESCRIPTION/BACKGROUND](#)  
[DISCLAIMER](#)  
[POLICY HISTORY](#)

## I. POLICY

Genetic testing to confirm a diagnosis of familial hypercholesterolemia (FH) may be considered **medically necessary** when a definitive diagnosis is required as an eligibility criterion for specialty medications (see Policy Guidelines) and when the following criteria are met:

- Genetic testing is targeted to individuals who are in an uncertain category according to clinical criteria (personal and family history, physical exam, lipid levels) (see Policy Guidelines); **AND**
- Alternative treatment considerations are in place for individuals who have an uncertain diagnosis of FH and a negative genetic test.

Genetic testing of children of individuals with FH to determine future risk of disease may be considered **medically necessary** when the following criteria are met (see Policy Guidelines):

- A pathogenic variant is present in a parent; **AND**
- General lipid screening is not recommended based on age or other factors.

Genetic testing to confirm a diagnosis of heterozygous FH is considered **investigational** in all other situations. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this testing.

Genetic testing of adults who are close relatives of individuals with FH to determine future risk of disease is considered **investigational** (see Policy Guidelines). There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this testing.

### Policy Guidelines

The definition of an “uncertain” diagnosis of familial hypercholesterolemia (FH) is not standardized. However, available diagnostic tools provide guidance on when a diagnosis is and

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

is not definitive. When FH is suspected and evaluated against standardized diagnostic criteria, it can be interpreted that the individual is in an “uncertain” category when criteria for a definitive diagnosis are not met. Here are some examples of certain criteria not being met:

- Dutch Lipid Clinic Criteria. A score of 8 or greater on the Dutch Lipid Clinic criteria is considered definitive FH. Scores between 3 and 7 are considered “possible” or “probable” FH. The latter 2 categories can be considered to represent “uncertain” FH.
- Simon-Broome Register Criteria. A definitive diagnosis of FH is made based on a total cholesterol level greater than 290 mg/dL in adults (or low-density lipoprotein >190 mg/dL), together with either positive physical exam findings or a positive genetic test. Probable FH, which can be interpreted as “uncertain” FH, is diagnosed using the same cholesterol levels, plus family history of premature coronary artery disease or total cholesterol of at least 290 mg/dL in a first- or a second-degree relative.
- Make Early Diagnosis Prevent Early Death (MEDPED) Diagnostic Criteria. These criteria provide a yes/no answer for whether an individual has FH, based on family history, age, and cholesterol levels. An individual who meets criteria for FH can be considered to have definitive FH; however, there is no “possible” or “probable” category that allows assignment of an “uncertain” category.

When there is a clinical diagnosis of FH but no known pathogenic variant in the family, it is necessary to test an index case to determine variant status.

It is unlikely that screening of adults who are close relatives of an index case of FH will improve outcomes because management decisions will be made according to lipid levels and will not differ based on a diagnosis of FH. However, there are conditions under which testing of relatives will lead to improved outcomes, particularly when testing is performed as part of a formal cascade screening program. Cascade testing refers to a coordinated program of population screening intended to identify additional patients with FH. Cascade screening may involve a combination of lipid levels and genetic testing; conversely, cascade screening may be performed with genetic testing alone. Beginning with an index case, close relatives are screened. For patients who screen positive, all close relatives are then identified and screened. This process is repeated until no further close relative eligible for screening can be identified. While such programs exist in Western Europe, there are barriers to implementation in the United States, such as a lack of an infrastructure to identify all individuals in the cascade; additionally, there exists a lack of coordination for patients with different types of medical insurance.

Eligibility for specialty medicines (e.g., PCSK9 inhibitors) may require a definitive diagnosis of FH. The labeled indications for these agents state they are indicated for individuals with FH, although criteria for diagnosis are not given. In the key trials that led to U.S. Food and Drug Administration approval of these inhibitors, having a diagnosis of FH served as an eligibility criterion. The diagnosis in these trials was based on clinical factors with or without genetic testing.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

### GENETICS NOMENCLATURE UPDATE

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the HUman Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology— “pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

<b>Previous Mutation</b>	<b>Updated</b>	<b>Definition</b>
	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

<b>Variant Classification</b>	<b>Definition</b>
<b>Pathogenic</b>	Disease-causing change in the DNA sequence
<b>Likely pathogenic</b>	Likely disease-causing change in the DNA sequence
<b>Variant of uncertain significance</b>	Change in DNA sequence with uncertain effects on disease
<b>Likely benign</b>	Likely benign change in the DNA sequence
<b>Benign</b>	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

### GENETIC COUNSELING

Genetic counseling is primarily aimed at individuals who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

### II. PRODUCT VARIATIONS

[TOP](#)

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations as discussed in Section VI. Please see additional information below.

**FEP PPO** - Refer to FEP Medical Policy Manual. The FEP Medical Policy manual can be found at: <https://www.fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies>

### III. DESCRIPTION/BACKGROUND

[TOP](#)

#### FAMILIAL HYPERCHOLESTEROLEMIA

Familial hypercholesterolemia (FH) is an inherited disorder characterized by markedly elevated low-density lipoprotein (LDL) levels, physical exam signs of cholesterol deposition, and premature cardiovascular disease. FH can be categorized as homozygous or heterozygous FH. Homozygous FH is an extremely rare disorder that arises from biallelic variants in a single gene, and the disorder has a prevalence of between 1:160,000 and 1:1,000,000. Individuals with homozygous FH have extreme elevations of LDL, develop coronary artery disease (CAD) in the second or third decade, and are generally diagnosed easily.

Heterozygous FH is more common, with an estimated prevalence between 1 in 200 to 1 in 500 individuals. Some populations, such as Ashkenazi Jews and South Africans, have a higher prevalence of up to 1 in 100. For affected individuals, the burden of illness is high. Patients with FH and increased LDL cholesterol (>190 mg/dL) have a three times higher risk of CAD than those with increased LDL cholesterol alone. The average age for presentation with CAD is in the fourth decade for men and the fifth decade for women, and there is a 30% to 50% increase in risk for men and women in the fifth and sixth decades, respectively. Increased risk of CAD is associated with a higher rate of death associated with cardiovascular causes in patients with homozygous and heterozygous FH.

#### Diagnosis

The diagnosis of FH relies on elevated LDL levels in conjunction with a family history of premature CAD and physical exam signs of cholesterol deposition. There is wide variability in cholesterol levels for patients with FH, and considerable overlap in levels between patients with FH and patients with non-FH. Physical exam findings can include tendinous xanthomas, xanthelasma, and corneal arcus, but these are not often helpful in making a diagnosis. Xanthelasma and corneal arcus are common in the elderly population and therefore not specific. Tendinous xanthomas are relatively specific for FH but are not sensitive findings. They occur mostly in patients with higher LDL levels and treatment with statins likely delays or prevents the development of xanthomas.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

Because of the variable cholesterol levels, and the low sensitivity of physical exam findings, there are a considerable number of patients in whom the diagnosis is uncertain. For these individuals, there are a number of formal diagnostic tools for determining the likelihood of FH.

- Make Early Diagnosis Prevent Early Deaths Program Diagnostic Criteria (MEDPED)
  - This tool relies on a combination of total cholesterol levels, age, and family history. For example, a 20-year-old individual who has no family history is diagnosed with FH if total cholesterol is 270 mg/dL or higher. A 25-year-old individual with a first-degree relative who has FH is diagnosed with FH if total cholesterol is 240 mg/dL or higher.
  - Genetic testing is not considered as part of the diagnostic workup with this tool.
- Dutch Lipid Clinic Criteria
  - This tool assigns points for family history, CAD in the individual, physical exam signs of cholesterol deposition, LDL levels, and results of genetic testing. The diagnosis of definite FH is made when the score is 8 or higher and probable FH when the score is 6 to 8.
  - The diagnosis can be made with or without genetic testing. A positive genetic test is given 8 points, which is the highest for any criterion and indicates that a positive genetic test alone is sufficient to make a definitive diagnosis.
- Simon-Broome Registry Criteria
  - Using these criteria, a definite diagnosis of FH is made based on total cholesterol is greater than 290 mg/dL in adults (or LDL >190 mg/dL) together with tendinous xanthoma in the individual or a first-degree relative.
  - A definite diagnosis can also be made using cholesterol levels and a positive genetic test.
  - Probable FH is diagnosed by cholesterol levels and either a family history of premature CAD or a family history of total cholesterol 290 mg/dL or higher in a first- or a second-degree relative.

### Treatment

Treatment of FH is generally similar to that for non-FH and is based on LDL levels. Treatment may differ in that the approach to treating FH is more aggressive (i.e., treatment may be initiated sooner, and a higher intensity medication regimen may be used). In adults, there are no specific treatment guidelines that indicate treatment for FH differs from standard treatment of hypercholesterolemia. There may be more differences in children, for whom the presence of a pathogenic variant may impact the timing of starting medications.

As with other forms of hypercholesterolemia, statins are the mainstay of treatment for FH. However, because of the degree of elevated LDL in many patients with FH, statins will not be sufficient to achieve target lipid levels. Additional medications can be used in these patients. Ezetimibe inhibits absorption of cholesterol from the gastrointestinal tract and is effective for reducing LDL levels by up to 25% in patients already on statins. The IMPROVED Reduction of

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

Outcomes: Vytorin Efficacy International Trial randomized patients with the acute coronary syndrome to a combination of ezetimibe plus statins vs statins alone and reported that cardiovascular events were reduced for patients treated with combination therapy.

The PCSK9 inhibitors are the most recently approved drugs for hyperlipidemia. These medications have potent LDL-lowering properties and have been tested in patients with FH. When added to statins, these drugs can result in additional LDL reduction of 30% to 70% and have been reported to reduce the incidence of nonfatal myocardial infarction. Other antilipid medications (e.g., bile acid sequestrants, niacin) are effective at reducing LDL levels but have not demonstrated efficacy in reducing cardiovascular events when added to statins. For patients who continue to have elevated LDL levels despite maximum medical treatment, lipid apheresis is an option.

### Genetic Markers for Familial Hypercholesterolemia

FH is generally inherited as an autosomal dominant condition. The primary physiologic defect in FH is the impaired ability to clear LDL from the circulation, resulting in elevated serum levels. Three genes have been identified as harboring variants associated with FH.

- The LDL receptor gene (*LDLR*) is the most common variant identified, accounting for between 60% and 80% of FH.
  - The LDL receptor binds LDL thus allowing removal of LDL from the circulation. A defect in the LDL receptor leads to reduced clearance of LDL.
  - Over 1500 different pathogenic variants have been identified in this gene. Characterization of the frequency and spectrum of variants is ongoing.
- The *APOB* gene accounts for approximately 1% to 5% of FH cases.
  - Apolipoprotein B is a cofactor in the binding of LDL to the LDL receptor, and variants in *APOB* lead to reduced clearance of LDL.
  - There are a limited number of variants of this gene, allowing targeted testing.
- The *PCSK9* gene accounts for approximately 0% to 3% of FH.
  - This variant results in increased PCSK9 levels, which impair the function of the LDL receptors leading to reduced clearance of LDL.
  - There are a limited number of known pathogenic variants, allowing targeted testing.

Penetrance for all FH genes is 90% or higher. Therefore, nearly all patients found to have a pathogenic variant will eventually develop clinical disease. There is some degree of variable clinical expressivity that might be mediated by both environmental factors such as diet and exercise, and unknown genetic factors that modify gene expression.

### REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

### IV. RATIONALE

[TOP](#)

#### Summary of Evidence

For individuals who have signs and/or symptoms of familial hypercholesterolemia (FH) when a definitive diagnosis is required to establish eligibility for specialty medications or who have signs and/or symptoms of FH undergoing lipid-lowering therapy who receive genetic testing to confirm the diagnosis of FH, the evidence includes case series and cross-sectional studies. Relevant outcomes are test validity, other test performance measures, symptoms, change in disease status, and morbid events. For clinical validity, there are large samples of individuals with FH who have been systematically tested for FH variants. In these cohorts of patients, the clinical sensitivity ranges from 30% to 70% for those with definite FH. For suspected FH, the sensitivity is lower, ranging from 1% to 30%. Clinical specificity ranges from 99% to 100%. False-positives are expected to be low for known pathogenic variants, but the false-positive rate is unknown for novel variants or for variants of uncertain significance. Direct evidence for clinical utility is lacking. The clinical utility of genetic testing was evaluated using a chain of evidence in the following situations:

- *When a definitive diagnosis of FH is required to establish eligibility for specialty medications.* A chain of evidence demonstrates that clinical utility is present. For patients who are in an uncertain diagnostic category, a positive genetic test can confirm the diagnosis of FH and establish eligibility for specialty medications. Specialty medications (e.g., proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitors) have known efficacy in patients with FH and uncontrolled lipid levels despite treatment with statins and/or other medications. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
- *All other situations.* Clinical utility of testing for diagnosis cannot be demonstrated through a chain of evidence. No changes in management occur as a result of establishing a definitive diagnosis with genetic testing compared with standard clinical evaluation. For adolescents and adults, measurement of lipid levels is indicated, and management decisions will be made primarily on lipid levels and will not differ in the presence of FH. Therefore, an improvement in health outcomes cannot be demonstrated. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are adults or children and have a close relative with a diagnosis of FH who receive genetic testing to determine future risk of FH, the evidence includes a randomized controlled trial (RCT), case series, and cross-sectional studies. Relevant outcomes include test validity, other test performance measures, symptoms, change in disease status, and morbid events. For clinical validity, there are large samples of individuals with FH who have been systematically tested for FH variants. In these cohorts, the clinical sensitivity ranges from 30% to 70% for those with definite FH. For suspected FH, the sensitivity is lower, ranging from 1% to

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

30%. Clinical specificity ranges from 99% to 100%. False-positives are expected to be low for known pathogenic variants, but the false-positive rate is unknown for novel variants or for variants of uncertain significance. Direct evidence for clinical utility is lacking. Clinical utility was evaluated using a chain of evidence in the following situations:

- *Adults.* Clinical utility cannot be demonstrated through a chain of evidence. While targeted genetic testing is superior to standard risk stratification for determining future risk of disease, it is unlikely that management changes will occur as a result of genetic testing. Adults who are close relatives of individuals with FH will have their lipid levels tested, and management decisions for adults are made primarily by low-density lipoprotein (LDL) levels and will not differ for patients with a diagnosis of FH. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
- *Children.* Clinical utility can be demonstrated through a chain of evidence. Targeted genetic testing is superior to standard risk stratification for determining future risk of disease. It is recommended that the children of individuals who have a pathogenic variant initiate screening at an early age; further, the affected children should begin treatment with statins as early as possible. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

### V. DEFINITIONS

[TOP](#)

NA

### VI. DISCLAIMER

[TOP](#)

*Capital Blue Cross' medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as required by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member's benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the members' benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross' Provider Services or Member Services.*

### VII. CODING INFORMATION

[TOP](#)

**Note:** This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

### Covered when medically necessary:

Procedure Codes							
81401	81405	81406					

ICD-10-CM Diagnosis Code	Description
E78.00	Pure hypercholesterolemia, unspecified
E78.01	Familial hypercholesterolemia
E780.10	Homozygous familial hypercholesterolemia [HOFH]
E780.11	Heterozygous familial hypercholesterolemia [HEFH]
E780.19	Familial hypercholesterolemia, unspecified
Z13.6	Encounter for screening for cardiovascular disorders
Z13.79	Encounter for other screening for genetic and chromosomal anomalies
Z83.42	Family history of familial hypercholesterolemia
Z84.81	Family history of carrier of genetic disease

### VIII. REFERENCES

[TOP](#)

1. McGowan MP, Hosseini Dehkordi SH, Moriarty PM, et al. Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia. *J Am Heart Assoc.* Dec 17 2019; 8(24): e013225. PMID 31838973
2. Youngblom E, Knowles JW. Familial Hypercholesterolemia. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews(R)*. Seattle, WA: University of Washington; 2014.
3. Bouhairie VE, Goldberg AC. Familial Hypercholesterolemia. *Endocrinol Metab Clin North Am.* Mar 2016; 45(1): 1-16. PMID 26892994
4. Patel RS, Scopelliti EM, Savelloni J. Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies. *Pharmacotherapy.* Dec 2015; 35(12): 1189-203. PMID 26684558
5. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. *Circulation.* Jun 02 2020; 141(22): 1742-1759. PMID 32468833
6. Khera AV, Won HH, Peloso GM, et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *J Am Coll Cardiol.* Jun 07 2016; 67(22): 2578-89. PMID 27050191
7. Mundal L, Igland J, Ose L, et al. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992-2013. *Eur J Prev Cardiol.* Jan 2017; 24(2): 137-144. PMID 27794106
8. Bilen O, Pokharel Y, Ballantyne CM. Genetic Testing in Hyperlipidemia. *Endocrinol Metab Clin North Am.* Mar 2016; 45(1): 129-40. PMID 26893002

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

9. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med.* Jun 18 2015; 372(25): 2387-97. PMID 26039521
10. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. *N Engl J Med.* Apr 16 2020; 382(16): 1520-1530. PMID 32197277
11. Chiou KR, Charng MJ. Genetic diagnosis of familial hypercholesterolemia in Han Chinese. *J Clin Lipidol.* 2016; 10(3): 490-6. PMID 27206935
12. Diakou M, Miltiadous G, Xenophontos SL, et al. Spectrum of LDLR gene mutations, including a novel mutation causing familial hypercholesterolaemia, in North-western Greece. *Eur J Intern Med.* Oct 2011; 22(5): e55-9. PMID 21925044
13. Hooper AJ, Nguyen LT, Burnett JR, et al. Genetic analysis of familial hypercholesterolaemia in Western Australia. *Atherosclerosis.* Oct 2012; 224(2): 430-4. PMID 22883975
14. Palacios L, Grandoso L, Cuevas N, et al. Molecular characterization of familial hypercholesterolemia in Spain. *Atherosclerosis.* Mar 2012; 221(1): 137-42. PMID 22244043
15. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. *Clin Genet.* Jun 2010; 77(6): 572-80. PMID 20236128
16. Tichý L, Freiburger T, Zapletalová P, et al. The molecular basis of familial hypercholesterolemia in the Czech Republic: spectrum of LDLR mutations and genotype-phenotype correlations. *Atherosclerosis.* Aug 2012; 223(2): 401-8. PMID 22698793
17. Abul-Husn NS, Manickam K, Jones LK, et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. *Science.* Dec 23 2016; 354(6319). PMID 28008010
18. Wang J, Dron JS, Ban MR, et al. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically. *Arterioscler Thromb Vasc Biol.* Dec 2016; 36(12): 2439-2445. PMID 27765764
19. Hedegaard BS, Bork CS, Kanstrup HL, et al. Genetic testing increases the likelihood of a diagnosis of familial hypercholesterolaemia among people referred to lipid clinics: Danish national study. *Atherosclerosis.* May 2023; 373: 10-16. PMID 37080006
20. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med.* Apr 16 2015; 372(16): 1500-9. PMID 25773607
21. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med.* Apr 16 2015; 372(16): 1489-99. PMID 25773378
22. Lee C, Rivera-Valerio M, Bangash H, et al. New Case Detection by Cascade Testing in Familial Hypercholesterolemia: A Systematic Review of the Literature. *Circ Genom Precis Med.* Nov 2019; 12(11): e002723. PMID 31638829
23. Miller AA, Bangash H, Smith CY, et al. A pragmatic clinical trial of cascade testing for familial hypercholesterolemia. *Genet Med.* Dec 2022; 24(12): 2535-2543. PMID 36173399

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

24. Ajufo E, deGoma EM, Raper A, et al. A randomized controlled trial of genetic testing and cascade screening in familial hypercholesterolemia. *Genet Med*. Sep 2021; 23(9): 1697-1704. PMID 34040191
25. Leren TP. Cascade genetic screening for familial hypercholesterolemia. *Clin Genet*. Dec 2004; 66(6): 483-7. PMID 15521974
26. National Heart Lung and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. n.d.; <http://www.nhlbi.nih.gov/health-pro/guidelines/current/cardiovascular-health-pediatric-guidelines/summary#chap9>. Accessed August 23, 2023.
27. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev*. Jul 07 2017; 7(7): CD006401. PMID 28685504
28. Migliara G, Baccolini V, Rosso A, et al. Familial Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient Management. *Front Public Health*. 2017; 5: 252. PMID 28993804
29. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. *Atherosclerosis*. Oct 2011; 218(2): 272-80. PMID 21762914
30. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation: executive summary. *J Atheroscler Thromb*. 2014; 21(4): 368-74. PMID 24892180
31. Jellinger PS, Handelsman Y, Rosenblit PD, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARY Complete Appendix to Guidelines available at <http://journals.aace.com>. *Endocr Pract*. Apr 02 2017; 23(4): 479-497. PMID 28156151
32. National Institute for Health and Care Excellence (NICE). Familial hypercholesterolaemia: identification and management. 2019; <https://www.nice.org.uk/guidance/cg71>. Accessed August 23, 2023.
33. Musunuru K, Hershberger RE, Day SM, et al. Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association. *Circ Genom Precis Med*. Aug 2020; 13(4): e000067. PMID 32698598
34. Landstrom AP, Kim JJ, Gelb BD, et al. Genetic Testing for Heritable Cardiovascular Diseases in Pediatric Patients: A Scientific Statement From the American Heart Association. *Circ Genom Precis Med*. Oct 2021; 14(5): e000086. PMID 34412507
35. Brown EE, Sturm AC, Cuchel M, et al. Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association. *J Clin Lipidol*. 2020; 14(4): 398-413. PMID 32507592
36. Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. *J Am Coll Cardiol*. Aug 07 2018; 72(6): 662-680. PMID 30071997

## MEDICAL POLICY

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

37. Watts GF, Gidding SS, Hegele RA, et al. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. *Nat Rev Cardiol.* Jun 15 2023. PMID 37322181
38. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics.* Dec 2011; 128 Suppl 5(Suppl 5): S213-56. PMID 22084329
39. US Preventive Services Task Force (USPSTF). Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication. 2022; <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/statin-use-in-adults-preventive-medication#bootstrap-panel--7>. Accessed August 23, 2023.
40. Lozano P, Henrikson NB, Dunn J, et al. Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA.* Aug 09 2016; 316(6): 645-55. PMID 27532919
41. Tada H, Kawashiri M-a, Nohara A, Sekiya T, Watanabe A, Takamura M. Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia. *Genes.* 2024; 15(3):297. doi.org/10.3390/genes15030297
42. Bigossi M, Siddiqui MK. Genetic testing for familial hypercholesterolaemia: utility beyond diagnosis. *European Journal of Preventive Cardiology.* 2022;31(7):e59-e61. doi:10.1093/eurjpc/zwac258
43. Brown EE, Byrne K, Michos ED, et al. Expanded Genetic testing in Familial Hypercholesterolemia—A single center’s experience. *American Journal of Preventive Cardiology.* 2024;18:100683. doi:10.1016/j.ajpc.2024.100683

### IX. POLICY HISTORY

[TOP](#)

<b>MP 2.363</b>	<b>06/01/2018 New Policy.</b> New BCBSA adoption policy. Genetic testing to confirm a diagnosis of familial hypercholesterolemia (FH) or future risk of disease may be considered medically necessary when criteria is met.
	<b>04/04/2019 Consensus Review.</b> Policy statement was not updated. References updated.
	<b>04/01/2020 Consensus Review.</b> Policy statement unchanged. References reviewed and updated. No coding changes.
	<b>04/30/2021 Consensus Review.</b> No change in policy statement. Background, Rationale and References updated.
	<b>11/30/2022 Consensus Review.</b> No changes in policy statement. References reviewed and updated. FEP statement updated.
	<b>11/07/2023 Consensus Review.</b> No changes to policy statement. Coding reviewed. References, rationale and policy guidelines updated.
	<b>12/02/2024 Consensus Review.</b> No changes to policy statement. References reviewed and updated. Coding reviewed with no coding changes.

**MEDICAL POLICY**

<b>POLICY TITLE</b>	<b>GENETIC TESTING FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA</b>
<b>POLICY NUMBER</b>	<b>MP 2.363</b>

<b>05/14/2025 Consensus Review.</b> No changes to policy statement. References reviewed. Coding reviewed with no coding changes.
<b>07/22/2025 Administrative Update.</b> Removed Benefit Variations Section and updated Disclaimer.
<b>09/02/2025 Administrative Update.</b> New ICD10 codes added Eff 10/01/2025
<b>03/05/2026 Retirement Review.</b> Service to be managed by the vendor Evicore.

[Top](#)

*Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company<sup>®</sup>, Capital Advantage Assurance Company<sup>®</sup> and Keystone Health Plan<sup>®</sup> Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital Blue Cross in its capacity as administrator of programs and provider relations for all companies.*